Lonsurf(tipiracil)
Lonsurf, Tipiracil / Trifluridine (tipiracil) is a small molecule pharmaceutical. Tipiracil was first approved as Lonsurf on 2015-09-22. It is used to treat colorectal neoplasms in the USA. It has been approved in Europe to treat colorectal neoplasms.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
Combinations
Lonsurf, Tipiracil trifluridine
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tipiracil hydrochloride
+
Trifluridine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LONSURF | Taiho Oncology | N-207981 RX | 2015-09-22 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lonsurf | New Drug Application | 2024-12-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| colorectal neoplasms | — | D015179 | — |
| virus diseases | — | D014777 | B34 |
| herpetic keratitis | EFO_0007308 | D016849 | — |
| infectious keratoconjunctivitis | — | D007639 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TIPIRACIL HYDROCHLORIDE / TRIFLURIDINE, LONSURF, TAIHO ONCOLOGY | |||
| 2026-02-22 | ODE-229 | ||
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
118 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rectal neoplasms | D012004 | — | — | 5 | 7 | — | — | — | 11 |
| Colonic neoplasms | D003110 | — | C18 | 4 | 6 | — | — | — | 10 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | 4 | — | — | — | 7 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | 5 | — | — | — | 5 |
| Cholangiocarcinoma | D018281 | — | C22.1 | 1 | 5 | — | — | — | 5 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | 3 | — | — | — | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 3 | — | — | — | 4 |
| Drug therapy | D004358 | — | — | 1 | 3 | — | — | — | 3 |
| Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 2 |
| Bile duct neoplasms | D001650 | — | — | — | 2 | — | — | — | 2 |
Show 21 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastrointestinal microbiome | D000069196 | — | — | — | — | — | — | 1 | 1 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | — | — | 1 | 1 |
| Urinary incontinence | D014549 | — | R32 | — | — | — | — | 1 | 1 |
| Alcoholic intoxication | D000435 | — | — | — | — | — | — | 1 | 1 |
| Alcohol abstinence | D064829 | — | — | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | — | 1 | 1 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | — | — | — | 1 | 1 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | — | — | — | 1 | 1 |
| Healthy volunteers/patients | — | — | — | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tipiracil |
| INN | tipiracil |
| Description | Tipiracil is a member of the class of pyrimidones that is uracil substituted by chloro and (2-iminopyrrolidin-1-yl)methyl groups at positions 5 and 6 respectively. Used (as the hydrochloride salt) in combination with trifluridine, a nucleoside metabolic inhibitor, for treatment of advanced/relapsed unresectable colorectal cancer. It has a role as an antineoplastic agent and an EC 2.4.2.4 (thymidine phosphorylase) inhibitor. It is a pyrimidone, an organochlorine compound, a carboxamidine and a member of pyrrolidines. It is functionally related to a uracil. It is a conjugate base of a tipiracil(1+). |
| Classification | Small molecule |
| Drug class | uracil type antineoplastics |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl |
Identifiers
| PDB | — |
| CAS-ID | 183204-74-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL235668 |
| ChEBI ID | — |
| PubChem CID | 6323266 |
| DrugBank | DB09343 |
| UNII ID | NGO10K751P (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 11,926 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,136 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use